MarketPulse

rights offering

3 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Na

AIM ImmunoTech Closes $1.8M Rights Offering to Fund Pancreatic Cancer Drug

AIM ImmunoTech closes $1.8M rights offering to advance Ampligen immunotherapy development for late-stage pancreatic cancer treatment.
AIMclinical trialswarrants
BenzingaBenzinga··Globe Newswire

AIM ImmunoTech Raises $1.8M Through Rights Offering as Biotech Seeks Capital

AIM ImmunoTech raises $1.8M through rights offering expiring March 3, 2026, providing working capital for ongoing immunotherapy operations.
AIMwarrantscapital raise
BenzingaBenzinga··Globe Newswire

Gabelli Equity Trust Marks Four Decades With Strong Returns and Shareholder Distribution

Gabelli Equity Trust celebrates 40 years with 27.32% returns in 2025 and maintains its 10% annual distribution policy, plus offers shareholders rights to purchase additional shares.
GAMItotal returnclosed-end fund